ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
As part of a pipeline revamp, Merck & Co. is returning assets to partners. Memphis-based GTx has reacquired the rights to a selective androgen receptor modulator program, including Ostarine, which has completed Phase II clinical trials to treat loss of body mass in cancer patients. GTx is now planning a Phase III trial of the drug. Separately, Merck paid Dynavax $4 million to cover expenses related to winding down their collaboration on the hepatitis B vaccine Heplisav. Merck ended the partnership after FDA put a trial on hold last year. The agency later allowed Dynavax to proceed, and the company now says it expects to file for approval in the third quarter of 2011.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter